Update on the everolimus-eluting coronary stent system: results and implications from the SPIRIT clinical trial program

Review

(5883) Total Article Views

Authors:

R Michael Kirchner, J Dawn Abbott

Published Date December 2009 Volume 2009:5 Pages 1089 - 1097

DOI: http://dx.doi.org/10.2147/VHRM.S5618

R Michael Kirchner, J Dawn Abbott

Department of Cardiology, Rhode Island Hospital, Brown Medical School, Providence, RI, USA

Abstract: Drug-eluting stents (DES) have had a major impact in interventional cardiology. Compared to bare metal stents, they significantly reduce restenosis and the need for target vessel revascularization. Four DES are available in the US, the first-generation sirolimuseluting (Cypher^®) and paclitaxel-eluting (Taxus^®) stents and later approved second-generation everolimus-eluting (Xience V^®) and zotarolimus-eluting (Endeavor^®) stents. The Xience V stent was approved on the basis of clinical efficacy and safety data from 3 studies in the SPIRIT clinical trial program. Within this trial series, the Xience V was superior to its bare metal stent counterpart, the Vision^® stent, and noninferior to the paclitaxel-eluting stent for target vessel failure at 9 months. This review provides a comprehensive assessment of the data derived from both the pre- and post-approval randomized controlled trials and registry studies of Xience V that comprise the SPIRIT clinical trial program including recently published mid-term outcomes. The implications of the results in terms of interventional practice will be discussed.

Keywords: cobalt-chromium, drug-eluting stent, everolimus, percutaneous coronary intervention, Xience V

Readers of this article also read: